Estrogen Receptor Alpha Mutations, Truncations, Heterodimers, and Therapies

Area of Science:

• Oncology
• Molecular Biology
• Endocrinology

Background:

• Breast cancer (BCa) mortality has decreased due to hormone therapies targeting estrogen receptor alpha (ERα).
• However, approximately 50% of ER-positive patients with high-risk BCa experience relapse and metastasis after endocrine therapy, indicating treatment inadequacy.
• Genomic alterations in ESR1, the gene for ERα, drive endocrine therapy resistance and BCa progression.

Purpose of the Study:

• To review the history and current understanding of ERα signaling in BCa.
• To explore the structural basis of ERα antagonism and aberrant signaling in therapy resistance.
• To discuss the evolution of endocrine therapies and emerging drug development strategies.

Main Methods:

• Literature review of historical and current research on ERα.
• Analysis of genomic abnormalities in ESR1 associated with endocrine resistance.
• Survey of current and future therapeutic strategies targeting ERα.

Main Results:

• ESR1 genetic lesions, including amplifications and mutations, promote ERα activity and therapy resistance.
• Aberrant ERα signaling drives tumor proliferation, metastasis, and treatment evasion.
• New therapies targeting ERα structural and transcriptional relationships show promise for resistant BCa.

Conclusions:

• Understanding ERα's complex roles and resistance mechanisms is crucial for improving BCa outcomes.
• Targeting ERα aberrations offers a promising avenue for developing more effective endocrine therapies.
• Continued investigation into ERα signaling and drug development is essential to combat BCa metastasis and mortality.